Demi X. Liu, Jun Zhou, Chenpan Nie, Annie An, Henry Q.X. Li, Jessie J.J.Wang, Crown Bioscience Inc.,
16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127
The mechanism of action of primary resistance to PD-1 blockade is largely unknown, however STK11/LKB1 alterations have been reported to have a significant role in primary resistance to PD-1/PD-L1 axis inhibitors in KRAS-mutant lung adenocarcinoma1-3. It is important to identify treatments which can rescue the efficacy of PD-1 blocker in STK11/LKB1-mutant patients. We have developed a STK11 knockout (KO) model using the CT26 colorectal cancer syngeneic line which harbors a KRAS mutation and evaluated the response to PD-1 alone and in combination with MEK inhibitors.